Abstract: The present invention concerns a method for producing a hydrogel comprising the following steps in succession: a first step (i) of providing at least one powder of an anionic polymer (A) and at least one chitosan powder (B) comprising amine functions (—NH2); a second step (ii) consisting in dry mixing at least the powders (A) and (B) from the first step in order to form a mixture of powders; a third step (iii) of suspending the mixture of powders obtained from the second step in an aqueous medium having a pH that can enable the anionic polymer (A) to be dissolved without dissolving the chitosan (B); a fourth step (iv) of adding an acid to the suspension obtained from the third step in order to form the hydrogel; or the third (iii) and fourth (iv) steps are replaced by a mixing fifth step (v), comprising mixing an acidified aqueous medium including at least one compound (C) comprising at least one unit of a hexose or a unit derived from a hexose, and/or at least one phosphate of said compound (C), with said

Abstract: The method allows controlling the quality of an initial RR series made up of a plurality of (RRi) samples which are respectively a function of time intervals (?ti) which separate two successive heartbeats. During this method, one resamples the RR series so as to obtain a resampled RR series, and one automatically controls the quality of the RR series by automatically calculating at least the mathematical norm value (NORME), in a sliding window, of the resampled RR series, said mathematical norm value being given by the following formula: NORME = ? i = 1 N ? ( RR i - 1 N ? ? i = 1 N ? ( RR i ) ) 2 where N is the number of RRi samples in said window.

Abstract: A device allowing the creation of an alimentary bolus flow between two stomas, including means forming a pump; first/second sealed connection means capable of connecting the suction opening to an upstream/downstream stoma located on the abdominal wall of a patient; and first and/or second anti-reflux means.

Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.

Abstract: A temporo-mandibular prosthesis including a glenoid part and a condylar part intended to be articulated relative to the glenoid part. The glenoid part including a glenoid support made in a metallic material; and a glenoid insert made in a non-metal lie material, and defining a seat for a head of said condylar part to define said articulation, wherein the glenoid support defines a housing having an opening through which said glenoid insert is insertable into said housing, said opening opening on an external side (E) of said glenoid support, the glenoid support comprising a tab configurable in a passive position and in an active position in which said tab allows and forbids, respectively, the insertion and the extraction, respectively, of said glenoid insert into and out of said housing, respectively.

Abstract: The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.

Abstract: The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).

Abstract: The present invention provides a method (30) of determining mechanical properties of the pelvic cavity of a person or an animal, the pelvic cavity including a plurality of organs and the method comprising a step (34) during which pressure is measured at one or more points of the surface of one of the organs of said pelvic cavity, and during which, simultaneously, movements of a plurality of organs of said pelvic cavity are also measured. The present invention also provides a measuring device for measuring pressure in an organ of the pelvic cavity in order to perform the above method (30). The measuring device comprises an optical fiber pressure sensor mounted in a non-metallic housing, and a closed flexible reservoir mounted in said non-metallic housing and having a surface, in particular a flexible surface, that constitutes a pressure measuring surface.

Abstract: The method allows controlling the quality of an initial RR series consisting of a plurality of (RRi) samples which are respectively a function of time intervals (?ti) which separate two successive heartbeats. During this method, one resamples the RR series so as to obtain a resampled RR series, and one automatically controls the quality of the RR series by automatically calculating at least the mathematical norm value (NORME), in a sliding window, of the resampled RR series, said mathematical norm value being given by the following formula: NORME = ? i = 1 N ? ( RR i - 1 N ? ? i = 1 N ? ( RR i ) ) 2 where N is the number of RRi samples in said window.

Abstract: A device enabling food bolus flow between two stomas, said device having a pump forming means (3), said pump forming means (3) having an entry opening and an exit opening and being suitable for sucking food bolus through said entry opening and releasing it through said exit opening. The device further includes: —first watertight connection means (11) suitable for connecting said entry opening to a upstream stoma (S1) located on a patient's abdominal wall; —second watertight connection means (1) suitable for connecting said exit opening to a downstream stoma (S2), located on said patient's abdominal wall; said pump forming means being able to be activated by a user and suitable for being mounted on a patient's body, particularly on said patient's abdomen, in such a manner that once said device is mounted onto said patient's abdomen, food bolus flow can circulate from said upstream stoma (S1) to said downstream stoma (S2) outside of said patient's abdomen.

Abstract: The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient.

Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods and kits for determining the human sperm quality.

Abstract: A pharmaceutical composition for its use in the prophylactic treatment of a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid, without said cationic-polysaccharide core being surrounded by any phospholipidic layer, and at least an antigen obtained from said pathogen.

Abstract: The method allows controlling the quality of an initial RR series consisting of a plurality of (RRi) samples which are respectively a function of time intervals (?ti) which separate two successive heartbeats. During this method, one resamples the RR series so as to obtain a resampled RR series, and one automatically controls the quality of the RR series by automatically calculating at least the mathematical norm value (NORME), in a sliding window, of the resampled RR series, said mathematical norm value being given by the following formula: NORME = ? i = 1 N ? ( RR i - 1 N ? ? i = 1 N ? ( RR i ) ) 2 where N is the number of RRi samples in said window.

Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.

Abstract: A method for the in vitro diagnosis of an invasive fungal infection by MALDI-TOF mass spectrometry. The method involves, providing a liquid biological sample from a mammal, said biological sample containing, in particular, proteins and/or lipids and/or salts and/or polysaccharides and/or oligosaccharides and/or monosaccharides capable of forming complexes with said proteins and/or lipids and/or salts; treating said sample with biological liquid so as to extract said polysaccharides and/or oligosaccharides and/or monosaccharides; determining, by MALDI-TOF mass spectrometry, whether or not there is present among said extracted polysaccharides, oligosaccharides and/or monosaccharides, at least one given compound of interest coming from said fungal microorganism and chosen from polysaccharides, oligosaccharides and monosaccharides; and deducing, if said given compound of interest is present in said sample, that said mammal is suffering from an invasive fungal infection.

Abstract: A device enabling food bolus flow between two stomas, said device having a pump forming means (3), said pump forming means (3) having an entry opening and an exit opening and being suitable for sucking food bolus through said entry opening and releasing it through said exit opening. The device further includes: —first watertight connection means (11) suitable for connecting said entry opening to a upstream stoma (S1) located on a patient's abdominal wall; —second watertight connection means (1) suitable for connecting said exit opening to a downstream stoma (S2), located on said patient's abdominal wall; said pump forming means being able to be activated by a user and suitable for being mounted on a patient's body, particularly on said patient's abdomen, in such a manner that once said device is mounted onto said patient's abdomen, food bolus flow can circulate from said upstream stoma (S1) to said downstream stoma (S2) outside of said patient's abdomen.

Abstract: A pharmaceutical composition for its use in the prophylactic treatment in a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a porous cationic-polysaccharide solid core, loaded with at least an anionic phospholipid without being surrounded by any phospholipidic layer and at least an antigen obtained from said pathogen.

Abstract: The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from Schistosoma haematobium, Schistosoma mansoni, Schistosoma bovis represented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.

Abstract: The invention relates to an implant (1) or prosthesis for treating a genital prolapse, characterized in that it comprises a support portion (41, 51), which has been preformed with a hollow shape in order to match the shape of an organ that is to be supported, and one or more bearing portions (42, 52), which extend away from the support portion (41, 51) so as to bear on bone or ligament structures in order to stabilize the implant.